Answers are grounded in this paper and cite their sources.
Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma. This Phase I, open-label study evaluated the pharmacokinetics and safety of a single 50-mg oral dose of valemetostat in participants with hepatic impairment (HI). In total, 24 participants were enrolled into 3 cohorts of mild HI (n = 8) and moderate HI (n = 8) according to the National Cancer Institute's Organ Dysfunction Working Group criteria, and matched healthy participants with normal hepatic function (HF; n = 8). In participants with mild and moderate HI, total valemetostat (bound + unbound) area under the concentration-time curve extrapolated to infinity was 23% lower (geometric mean ratio [GMR], 77.2% [90% confidence interval (CI), 44.0-135]) and 35% lower, (GMR, 64.8% [90% CI, 40.6-103]), respectively, and unbound valemetostat was 19% lower (GMR, 81.1% [90% CI, 47.4-139]) and 15% higher (GMR, 115% [90% CI, 75.5-176]), than in participants with normal HF. No treatment-related adverse events were reported. Based on the result of this trial, no dosing adjustments are recommended for patients with mild to moderate HI receiving valemetostat.
No takes yet. Share an insight, caveat, or question.
Tachibana et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: